Ricerc@Sapienza

BRCA1/2 mutations play a predictive role in ovarian cancer risk evaluation. Moreover , patients are today being tested for BRCA1/2 mutations to select a tailored therapy too , because they could benefit from a treatment with PARP inhibitors (PARPi).Therefore in ovarian carcinomas (OCs), BRCA1/2 mutation testing is an important step in planning the correct therapeutic strategy in association with chemotherapy and anti VEGF agents. We read with great interest the paper submitted by Vos et al (1) which investigates the role of universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition. With the approach described by the authors, both hereditary and somatic aberrations affecting DNA BRCA1/2 could be quickly and correctly detected with tumor BRCA1/2 smMIP-based next generation sequence testing.